The CAV1 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian epithelial carcinoma cell line. This product provides a heterogeneous pool of gene-disrupted cells, enabling loss-of-function studies of the CAV1 gene without clonal selection. The polyclonal format preserves population-level heterogeneity, which can mitigate clonal artifacts and better represent the complexity of gene function in cancer biology. These cells serve as a robust in vitro model for investigating caveolin-1?Cdependent processes, including endocytosis, signal transduction, and lipid metabolism.
The A2780 parental cell line was originally established from an untreated patient with ovarian endometrioid adenocarcinoma, making it a widely used model for ovarian cancer research and drug resistance studies. A2780 cells retain key characteristics of epithelial ovarian carcinoma, including responsiveness to platinum-based chemotherapeutics and ease of genetic manipulation. This background is particularly relevant for examining the role of tumor suppressors in ovarian cancer progression and therapeutic response.
CAV1 encodes caveolin-1, the principal scaffolding protein of caveolae, which are flask-shaped plasma membrane invaginations. Caveolin-1 organizes signaling complexes by directly interacting with and modulating the activity of Src family kinases, H-Ras, EGFR, PDGFR, eNOS, integrin beta1, TGF-beta receptor I, and heterotrimeric G protein alpha subunits. Upstream, CAV1 expression is transcriptionally regulated by SREBP1, EGR-1, PPARgamma, STAT3, and p53, and is induced by integrin ligands, EGF, and PDGF. Downstream, caveolin-1 influences eNOS activity, Src kinase, ERK1/2, AKT, TGF-beta receptor signaling, and beta-catenin/Tcf transcriptional activity. Knockout of CAV1 abolishes caveolae formation, leading to dysregulated endocytosis and enhanced signaling through Src/FAK/ERK and PI3K/AKT pathways, with altered beta-catenin and Smad2/3-dependent transcription. This molecular rewiring may promote cell proliferation, migration, and altered drug sensitivity, consistent with the tumor-suppressive roles of CAV1 in ovarian cancer.
In the A2780 background, CAV1 loss-of-function provides a powerful tool for dissecting ovarian cancer biology. CAV1 is frequently downregulated in ovarian carcinomas, and its loss is associated with increased tumor aggressiveness and chemoresistance. This polyclonal knockout model enables the study of caveolin-1?Cdependent regulation of endocytic trafficking, lipid raft organization, and oncogenic signaling networks. Researchers can employ these cells to compare drug sensitivity profiles, particularly to cisplatin and paclitaxel, using proliferation and apoptosis assays such as MTT and flow cytometry. Additionally, the impact of CAV1 disruption on cell migration and invasion can be assessed via Transwell assays, while immunofluorescence and western blotting validate downstream effector changes.
Typical applications include mechanistic studies of caveolar endocytosis using transferrin uptake assays, analysis of signal transduction by phospho-ERK/AKT western blotting, and investigation of tumor microenvironment interactions through co-culture systems. Transcriptomic profiling by RNA-seq and co-immunoprecipitation of caveolin-1?Cinteracting partners further expand the utility of this model. These cells are suitable for advanced ovarian cancer research, drug discovery screening, and functional genomics studies aimed at elucidating the tumor-suppressive functions of CAV1. For additional information, technical support, or custom applications, please contact Ascent Research.
